Perrigo Company Stock News

The company recovered nicely from the challenges of the coronavirus pandemic, as indicated by its Q4 results.

Perrigo Company plc (PRGO) CEO Murray Kessler on Q4 2021 results - Earnings Call Transcript

Perrigo Company plc (NYSE: PRGO ) Q4 FY21 sales increased 4.9% Y/Y to $1.1 billion , in line with the consensus of $1.10 billion, led by a strong rebound in demand for cough/cold products. Acquisitions accounted for 0.2% growth points, while unfavorable currency movements offset growth by 0.8%. Organic net sales growth was … Full story available on Benzinga.com

Shares of Perrigo Co. gained 2.7% in premarket trading on Tuesday after the drug maker beat on earnings expectations for the final three months of the year. Perrigo had net income of $32.1 million, or 24 cents per share, in the fourth quarter of 2021. It reported a loss of $52.2 million, or 39 cents per share, in the same quarter a year ago. Adjusted earnings per share were 60 cents, compared with the FactSet consensus of 56 cents. Perrigo said revenue jumped 4.9% to $1.10 billion in the fourth quarter of the year, driven by higher sales during the cough and cold season and in its nutrition and skincare businesses. That''s up from $1.05 billion in the final three months of 2020. The FactSet consensus was $1.1 billion. Perrigo''s stock is down 15.9% over the past year, while the broader S&P 500 is up 14.7%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Perrigo press release (PRGO): Q4 Non-GAAP EPS of $0.60 beats by $0.04.Revenue of $1.1B (-14.7% Y/Y) in-line.Fiscal 2022 Outlook: Net sales growth of 3.5% to 4.5%, inclusive of…

DUBLIN, March 1, 2022 /PRNewswire/ -- Highlights: Fourth quarter net sales grew 4.9%, or 5.7% excluding the impact of currency, compared to the prior year to $1.1 billion led by a strong rebound in the demand for cough/cold products. Fiscal year 2021 net sales increased 1.2%, or down 0.3%…

Perrigo (NYSE:PRGO) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open.The consensus EPS Estimate is $0.56 (-39.8% Y/Y) and the consensus…

DUBLIN, Feb. 25, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) today announced that President and CEO, Murray S. Kessler and CFO Ray Silcock are scheduled to present at the Raymond James 43rd

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Perrigo (NYSE:PRGO) declares $0.26/share quarterly dividend, 8.3% increase from prior dividend of $0.24.Forward yield 2.7%Payable March 17; for shareholders of record Feb. 28; ex-div Feb.

DUBLIN, Feb. 15, 2022 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its fourth quarter and fiscal year 2021 financial results on Tuesday, March 1, 2022. The Company will also host a conference call beginning at 8:30 A.M. (EST). The conference…

After losing some value lately, a hammer chart pattern has been formed for Perrigo (PRGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio

Pune, India, Jan. 10, 2022 (GLOBE NEWSWIRE) -- The global OTC drugs market size is projected to grow from USD 157.0 billion in 2021 to USD 233.6 billion in 2028. The rising number of private label products is set to affect growth positively. In the U.S., shares of these products reached 31.0% in 2018 from 26.0% in 2009. Also, numerous companies are collaborating with e-commerce platforms to launch their products on their platforms. Amazon.com, Inc., for instance, introduced Perrigo''s over-the-counter healthcare products in February 2018. Fortune Business Insights mentioned this in a published report, titled, " OTC Drugs Market, 2021-2028 ." The report further states that the market stood at USD 148.0 billion in 2020. It is set to showcase a CAGR of 5.8% in the forecast period during 2021-2028. Request Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/over-the-counter-otc-drugs-market-105433 Dr Reddy''s Laboratories Unveils Famotidine Tablets in U.S. to Treat GERD In October 2020, Dr Reddy''s Laboratories, a multinational pharmaceutical company headquartered in India introduced the Famotidine tablet, an OTC drug for the treatment of gastroesophageal reflux disease (GERD) in the U.S.

Perrigo (NYSE:PRGO) and Assertio (NASDAQ:ASRT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations. Institutional & Insider Ownership 88.7% of Perrigo shares are owned by institutional investors. Comparatively, 19.0% of Assertio shares []